NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) And Strengthens Clinical Leadership
NexBio announces the completion of its First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181 safety in healthy subjects. The study drug was well tolerated at all dose levels.
More: continued here
Filed under: Respiratory on January 25th, 2009
You must be logged in to post a comment.